EIF2AK3 and non-small cell lung carcinoma: In line with these results, high pAKT levels have been linked to better response to neoadjuvant chemotherapy in breast cancer patients [54], and low pERK expression has been correlated with longer survival of NSCLC patients receiving neoadjuvant chemotherapy [55].